Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Operating Cash Flow
Cash generated by the company's core business operations during the period.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow dips below year-ago levels
Q1 FY2026 operating cash flow of $5.12M fell 74.3% year over year, behind the +42.9% change in trailing-twelve-month operating cash flow. Sequentially, it fell 93.1% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.
Context
- Operating cash flow amounted to 42.9% of revenue in FY2025, up 13.4 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -74.3% toward the trailing-twelve-month pace of +42.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 127.04M USD
- Year-over-year change
- +22.7%
- 4-year CAGR
- -16.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 127.04M | +22.7% |
| FY2024 | 2024-12-31 | 103.55M | -43.5% |
| FY2023 | 2023-12-31 | 183.43M | -33.0% |
| FY2022 | 2022-12-31 | 273.76M | +4.5% |
| FY2021 | 2021-12-31 | 261.9M | — |
Operating Cash Flow vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's LTM Mar 2026 operating cash flow of $112.21M is the 2nd largest of the 3 companies compared; the peer median is $142.79M.
- Its year-over-year change of +42.9% is the 2nd highest of 3, against a peer median of +15.1%.
- Operating cash flow amounts to 31.0% of revenue for IRWD, versus a peer median of 142.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $249.32M | +54.0% | +28.3% | 275.5% | |
| LTM Mar 2026 | $112.21M | +42.9% | -22.6% | 31.0% | |
| LTM Mar 2026 | $36.26M | -23.7% | -15.4% | 8.5% | |
| Peer median (excluding IRWD) | $142.79M | +15.1% | +6.5% | 142.0% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.45M | 175.07M | (1B) | 880K | 24.02M |
| Depreciation & Amortization | 1.5M | 1.42M | 1.58M | 2.01M | 1.88M |
| Deferred Income Tax | (333.29M) | 65.74M | 72.64M | 68.09M | 40.8M |
| Stock-Based Compensation | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M |
| Change in Working Capital | 17.73M | 2.82M | 11.28M | 739K | 39.65M |
| Accounts Receivables | 7.71M | 7.99M | 924K | 47.24M | 35.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.64M) | (8.12M) | 12.38M | (20.21M) | 6.2M |
| Other Working Capital | 12.66M | 2.94M | (2.03M) | (26.29M) | (1.7M) |
| Other Non-Cash Items | 25.23M | 1.67M | 1.07B | 1.98M | 3.45M |
| Operating Cash Flow | 261.9M | 273.76M | 183.43M | 103.55M | 127.04M |
| Capital Expenditures | (265K) | (136K) | (273K) | (142K) | (34K) |
| Acquisitions (Net) | 0 | 0 | (1.03B) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (265K) | (136K) | (1.03B) | (142K) | (34K) |
| Debt Repayment | 0 | (120.7M) | 300M | (115M) | 0 |
| Common Stock Issued | 19.58M | 9.54M | 6.36M | 11.01M | 216K |
| Common Stock Repurchased | (24.13M) | (126.39M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.58M | 9.54M | (29.2M) | (2.98M) | 0 |
| Financing Cash Flow | (4.55M) | (237.55M) | 277.16M | (106.97M) | 216K |
| Effect of Forex Changes | 0 | 0 | (53K) | (32K) | (329K) |
| Net Change in Cash | 257.08M | 36.07M | (565.78M) | (3.6M) | 126.9M |
| Free Cash Flow | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.